Allife Medicine is an international pharmaceutical company founded by scientists from China and the United Kingdom specialising in induced pluripotent stem cell (iPSC) technology and aiming to develop affordable,innovative,and universally applicable cell and gene therapies. Allife Medicine has received multiple awards in Cell and Gene Therapies (CGT) in China and internationally and was recognised as the most influential company in the CGT sector in 2022-China,GHP2023,LSR2024. As a platform company,we have established three major sectors: cell therapy,gene therapy and tumour immunotherapy,and we are proud to be the first in China to achieve industrial-scale production and clinical translation of iPSC. The clinical approvals for our CAR-NK and iPSC-derived endothelial progenitor cell (EPC) cell drugs put us at the forefront of the domestic cell therapy market.Our CAR-NK cell injection for the treatment of ovarian cancer received clinical approval in 2021,and EPC injection for the treatment of Acute Ischemic Stroke has entered clinical trials since April 2022.The two mentioned drugs have received the first approval in cell therapy clinical trials in the related field from the China Drug Administration. We have 190 employees,of which 140 are research and development staff,including 42 PhDs.The team has published over 80 papers and holds 116 patents,with many related to downstream differentiation of iPSCs and a comprehensive patent portfolio for CAR-NK technology. Our business model comprises three major segments: 1.Supplying and licensing cell lines and product pipelines; 2.Cell medicine and gene therapy via Independent research, development and commercialisation;3.Collaborative development and CDMO services. We aim to complete the Phase I clinical trial for acute ischemic stroke and submit IND applications for another two mature pipelines in 2024. Simultaneously,we plan to relocate and establish laboratories and manufacturing facilities in Beijing and the USA.